Axl downstream targeting unravels synergistic drug combinations in ovarian carcinoma cells

Research output: Contribution to journalArticlepeer-review


Background: Platinum-based therapy represents the main pharmacological treatment for ovarian carcinoma. Since molecular targeting of receptor tyrosine kinases (RTK) affects factors that may modulate drug response, the aim of this study was to examine whether downstream targets of AXL RTK could be exploited to improve cell response to cisplatin. Materials and Methods: Inhibitors of p38 (SB203580) and of signal transducer and activator of transcription 3 (stattic) were employed in combination with cisplatin in ovarian carcinoma cell lines. Apoptosis assay and western blot analysis were performed to evaluate cell response after treatment. Results: SB203580 produced a synergistic effect in combination with cisplatin in cisplatin-resistant IGROV-1/Pt1 cells. In addition, a favorable drug interaction was observed in A2780 cells when pre-incubated with cisplatin prior to stattic. The analysis of cell response after combined treatment showed down-regulation of the pro-apoptotic protein BCL2-associated agonist of cell death (BAD). Conclusion: Our results support the notion that downstream targets of AXL in ovarian carcinoma cells can be exploited to increase cisplatin activity in ovarian carcinoma models.

Original languageEnglish
Pages (from-to)3803-3808
Number of pages6
JournalAnticancer Research
Issue number7
Publication statusPublished - Jan 1 2019


  • AXL
  • Cisplatin
  • Ovarian carcinoma
  • P38 MAPK

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Axl downstream targeting unravels synergistic drug combinations in ovarian carcinoma cells'. Together they form a unique fingerprint.

Cite this